The GUARDIAN Trial - Induction Agent Sub-Study for Major Surgery

This study is looking at different ways to manage blood pressure and anesthesia during major surgery. It's a sub-study of a larger trial, and it specifically compares two anesthetic medications: etomidate and propofol. Researchers want to see if one of these medications, when used for anesthesia induction (the start of anesthesia), leads to fewer major complications related to blood flow after surgery. You might be able to join if you are at least 45 years old, scheduled for major non-heart surgery expected to last at least two hours, and will have general or neuraxial anesthesia. The study aims to enroll 6254 participants, but its current status is unclear.

Study design
This interventional study involves participants being randomly assigned to receive either etomidate or propofol for anesthesia induction, in addition to different blood pressure management strategies. It plans to enroll 6254 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 30 days after major non-cardiac surgery to check for major perfusion-related complications.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04934683

The GUARDIAN Trial - Induction Agent Sub-Study

Enrolling by Invitation
PHASE4Ages 45+InterventionalPrevention
The University of Texas Health Science Center, Houston
~6,254 participants
Updated 2025-08-29 on ClinicalTrials.gov
What's tested:Routine Blood Pressure ManagementTight Blood Pressure ManagementEtomidate InductionPropofol Induction

At a glance

Recruiting sites
0 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with a Composite of Major Perfusion-Related Complications
Measured over During the initial 30 days after major non-cardiac surgery
Major Surgery
11 sites across 6 states
China4
Ohio3
Nebraska1
Shanghai Municipality1
Greece1
Japan1
  • Daniel I Sessler, MD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Number of Participants with a Composite of Major Perfusion-Related ComplicationsDuring the initial 30 days after major non-cardiac surgery

    The primary outcome is a composite of major perfusion-related complications (myocardial injury, stroke, non-fatal cardiac arrest, Stage 2-3 acute kidney injury, deep or organ-space infection, sepsis, and death) in the 30 days after major non-cardiac surgery.